Recent Patents on Anti-Cancer Drug Discovery

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Volume 18 , Issues 4, 2023

This journal supports open access

Back Journal Home
Submit Abstracts Submit Manuscripts

Editorial Board


pra Editor-in-Chief rpacdd_ebm_chen_001 Chen Zhe-Sheng (Jason) Institute for Biotechnology College of Pharmacy and Health Sciences St. John's University New York NY USA 17437 citations

Dr. Chen obtained a doctorate (Ph.D.) in Pharmacology from the Kagoshima University, Japan. He also holds an MD degree from Guangdong Medical and Pharmaceutical College and a Master's degree in Toxicology from Sun Yat-Sen University, China. Currently, Dr. Chen is a Professor at St. John’s University College of Pharmacy and Health Sciences. He is also a director of the Institute for Biotechnology at St. John’s University. He has published ~340 scientific publications including Chemical Society of Review, Molecular Cancer, Drug Resistance Updates, Cancer Research, and Journal Biological Chemistry etc. Besides, he is the founding Editor in Chief of the Journal of Cancer Research Updates, an Editor-in-Chief of the Journal of New Developments in Chemistry, an editor of Bosnian Journal of Basic Medical Sciences and an associate editor of European Journal of Gynaecological Oncology, Frontiers in Cell and Developmental Biology, Frontiers in Oncology and Frontiers in Pharmacology. He is also an editorial board member of 29 journals and a reviewer of more than 270 peer-reviewed journals.

chenz@stjohns.edu
Associate Editors rpacdd_ebm_ronconi_001 Ronconi Luca School of Chemistry National University of Ireland Galway Galway Ireland

Dr. Ronconi (MChem, PhD, MRSC) obtained theMChemDegree (2000) and the PhD in Chemistry (2004) from the University of Padova (Italy). After one year of postdoctoral research at the sameuniversity, he took up a Marie Curie postdoctoral fellowship and, afterwards, a Körber Foundation postdoctoralfellowship at the University of Edinburgh (UK). In 2008he was appointed Assistant Professor of Chemistry at the University of Padova (Italy), and since2013 he is Lecturer in Chemistry at the National University of Ireland Galway (Ireland). His current researchinterests focus on the design of metal-based anticancer and imaging agents targeting specific biomarkers up-regulated in tumor cells for the targeted chemotherapy and diagnosis.

luca.ronconi@nuigalway.ie
rpacdd_ebm_sapino_001 Sapino Anna Department of Medical Sciences University of Turin Turin Italy

Anna Sapino obtained her Medical Degree (M.D.) at the University of Turin (IT) and the specialization in Surgical Pathology at the University of Milan (IT). She is full professor of Pathology at the University of Torino. Currently Dr. Sapino is the Scientific Director of the Candiolo Cancer Institute Fondazione del Piemonte per l’Oncologia- FPO-IRCCS. She has published more than 280 scientific works.

anna.sapino@unito.it
Regional Editors rpacdd_ebm_amedei_001 Amedei Amedeo Department of Experimental and Clinical Medicine Section of Internal Medicine -Immunology Division University of Florence Firenze Italy

Amedeo Amedei in 1996 he graduated with full marks and honours in Biology at Florence University. He started his scientific career studying the role of Th1/Th2 lymphocytes in GVHD, atopic dermatitis and kidney rejection. After he examined the role of Helicobacter pylori-specific immune response in gastric diseases. In 2003 began his doctor’s degree in "Clinical and Sperimental Medicine". In 2005 he became researcher at Department of Experimental and Clinical Medicine (University of Florence), where in 2015 he was appointed Associate Professor. Recently, the Prof. Amedei has focused his scientific interests on the cancer immunology. The great quality of his international profile is documented by scientific production: 126 peer reviewed articles (3474 Citations), 6 book chapters and one patent. The Prof. Amedei is serving as an editorial board member of 56 international journals and carries out activities as scientific reviewer for international research projects of private and public entities.

aamedei@unifi.it amedeo.amedei@unifi.it
Apostolopoulos Vasso Institute for Health and Sport Victoria University Melbourne Australia

Professor Vasso Apostolopoulos received her PhD majoring in immunology in 1995 from the University of Melbourne, Melbourne, Australia. Currently, she is the Pro Vice-Chancellor - Research Partnerships at Victoria University, Melbourne, Australia. Her expertise is multi-disciplinary with extensive expertise in immunology, x-ray crystallography, medicinal chemistry, cellular biology, molecular biology, and she has extensive translational research expertise with development of drugs and vaccines. Prof. Apostolopoulos as an author/co-author, has published more than 320 articles in various journals of international repute, accumulating more than 9,960 total citations.

vasso.apostolopoulos@mail.com vasso@burnet.edu.au
rpacdd_ebm_budillion_001 Budillon Alfredo National Cancer Institute - G. Pascale Napoli Italy

Dr. Budillon graduated in Medicine and passed the Specialty Certification in Oncology at University Federico II, Naples, Italy. He obtained the PhD in Oncology from University G. D’Annunzio of Chieti, Italy, and a Master degree in Health economy, Management and Bioethics. Dr. Budillon is the chief of Experimental Pharmacology, National Cancer Institute G. Pascale, Naples, Italy. He is also Adjunct Professor in Temple University’s College of Science and Technology, Philadelphia, PA, USA, and author of more that 130 publications and of a patent. He is also member of the Editorial Advisory Board of Reviews On Recent Clinical Trials, published by Bentham Science.

abudillon@yahoo.com
rpacdd_ebm_chan_001 Chan Andrew M. Faculty of Medicine, School of Biomedical Sciences The Chinese University of Hong Kong Shatin Hong Kong

Dr. Andrew M. Chan is a Professor and Chief of the Cancer Biology & Experimental Therapeutics Programme at the School of Biomedical Sciences of The Chinese University of Hong Kong. He obtained his Ph.D. degree from The Institute of Cancer Research in London in 1989 and conducted postdoctoral training at the US National Cancer Institute. He joined the Mount Sinai School of Medicine as an assistant professor and was recruited to the Medical College of Wisconsin as a full professor. Dr. Chan published 61 peer-reviewed articles in high impact journals including Science, Nature Genetics, PNAS, Cancer Cell, and Blood.

andrewmchan@cuhk.edu.hk
rpacdd_ebm_c-y-chen_001 Chen Chung-Yi School of Medical and Health Sciences Fooyin University Kaohsiung Taiwan

President Chen obtained PhD in 1999 at Kaohsiung Medical University. Currently teaches in Fooyin University, as most young is also the most senior professors and deans. The past 20 years, he has his scientific interests focused on life-threatening diseases, including traditional Chinese medicine used for cancer research. President Chen was just over 45 years old, but his work has more than 200 papers, Taiwan one of the young talents. Professor Chen was invited more than 70 kinds of Journal editorial boards. Professor Chen won numerous awards at home and abroad, from 2015, was awarded the lifetime achievement award.

xx377@fy.edu.tw
rpacdd_ebm_kostova_001 Kostova Irena Department of Chemistry Medical University Sofia Bulgaria

Irena Kostova received her PHD from MU-Sofia. She has published hundreds of publications with more than 3300 citations. Her research interests include the developmental work of coordination chemistry, theoretical chemistry, vibrational spectroscopy, pharmacological investigations on biologically active compounds, etc.

irenakostova@yahoo.com
rpacdd_ebm_lichtor_001 Lichtor Terry Department of Neurosurgery Rush University Medical Center IL United States

Terry Lichtor, MD, PhD is a practicing neurosurgeon. He has a number of research interests, and his brain tumor work is largely focused on the development of a DNA vaccine for treatment of primary and metastatic intracerebral tumors. In particular Dr. Lichtor has shown that vaccines prepared by transfer of DNA from the tumor into a highly immunogenic cell line stimulates an antitumor immune response which may be efficacious in the treatment of patients with brain tumors. Other research interests include developing a passive immunotherapeutic strategy for treatment of Alzheimer’s Disease. In addition, he has been involved in the development of a non-invasive MRI technique to measure intracranial pressure and brain compliance, and has been exploring the efficacy of this modality in managing a variety of patients with neurologic problems where intracranial pressure is an issue. Dr. Lichtor is a member of the neurosurgery faculty at Rush University Medical Center in Chicago, Illinois.

Terry_Lichtor@rush.edu
rpacdd_ebm_munaron_001 Munaron Luca Department of Animal Biology University of Torino Torino Italy

Dr. Luca Munaron obtained his Ph.D. in Physiology from the University of Milan (Italy) and is currently Associate Professor in Physiology at the University of Turin (Italy).

He is a member of the Editorial Board of several international journals and served as an Editor for special issues.

Dr. Munaron published more than 70 full papers on indexed journals and its work reached more than 1800 citations.

luca.munaron@unito.it
Rao Jianyu Division of Pathology University of California at Los Angeles CA USA

Professor Jianyu Rao got his PhD degree in 1984 from Shanghai Medical University, Shanghai, China. Currently, he is a tenured full professor and vice chair of the department of pathology and laboratory medicine at University of California at Los Angeles (UCLA), USA. His main clinical expertise includes cytology (especially urine cytology), Fine Needle Aspiration service, molecular cytology, gynecological pathology, and genitourinary tract pathology. Prof. Rao has published more than 195 articles in various journals of international repute, accumulating more than 8,100 total citations.

jrao@mednet.ucla.edu
rpacdd_ebm_h-sun_001 Sun Hongbin Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease and State Key Laboratory of Natural Medicines China Pharmaceutical University Nanjing China

Dr. Sun obtained a doctorate (Ph.D.) in Medicinal Chemistry from China pharmaceutical University in 1995. Currently Dr. Sun is a Professor in China pharmaceutical University. He has published more than 180 scientific publications and is the inventor of more than 30 patent applications. Dr. Sun’s major research interest is target verification and drug discovery for metabolic diseases and cancer. The leading drug candidate developed by Dr. Sun is Vicagrel (an anti-platelet agent in phase I clinical trial).

hongbinsun@cpu.edu.cn
Country Editor rpacdd_ebm_ribatti_001 Ribatti Domenico Dipartimento di Scienze Mediche di Base, Neuroscienze ed Organi di Senso Università degli Studi di Bari Bari Italy

Domenico Ribatti was born in Andria, Italy, on December 27, 1956. He was awarded his M.D. degree in October 1981, with full marks. In 1983, Dr. Ribatti joined the Medical School as Assistant at the Institute of Human Anatomy, University of Bari, Italy. In 1984, he took the specialization in Allergology. In 1989, he spent one year in Geneva, working at the Department of Morphology (Prof. R. Montesano). In 2008, he received the honoris causa degree in Medicine and Pharmacy from the University of Timisoara, Romania. His present position is full professor of Human Anatomy at the University of Bari Medical School.

domenico.ribatti@uniba.it
Section Editors rpacdd_ebm_Jin-sa_001 Cancer Neuroscience Jin Wei-Lin Institute of Cancer Neuroscience Medical Frontier Innovation Research Center The First Hospital of Lanzhou University Lanzhou P.R. China

Dr. Jin is a Professor at Lanzhou University. He received his Ph.D. and M.D. degrees from the Fourth Military Medical University followed by famous neurobiologist Prof. Gong Ju, a CAS member. In 2006, he joined the Institute of Neurosciences at Shanghai Jiao Tong University as an Associated Professor. In 2021, he was recruited to Lanzhou University. His lab is focused on molecular mechanism of axon regeneration, tumor epigenetics and cancer neuroscience. As PI, Dr. Jin was rewarded four grants from National Natural Science Foundation of China in the last five years. He has published more than 100 peer-reviewed publications and their findings have been published in some important professional journals, such as Cell, Nature Communications, Trends Pharmacol Sci, Cancer Res, Cell Death and Differentiation, Biomaterials, Pharmacology & Therapeutics, Med Res Rev, Cancer Letters, Molecular and cellular Neuroscience, J Comp Neurol and Anesthesiology.

rpacdd_ebm_Sergi-sh_001 Sergi Consolato M. Department of Laboratory Medicine and Pathology University of Alberta Hospital Edmonton Canada Rare Tumours

Consolato M. Sergi is Professor of Pathology and Pediatrics (Adj. Prof.), University of Alberta. Dr. Sergi was born in Rome (Italy), obtained his MD degree with honors at the University of Genoa, Italy, his Human Pathology degree at the University of Heidelberg, Germany, the title of hon. Clinical Reader of the University of Bristol, UK, his PhD/Habilitation at the University of Innsbruck, Austria, his MSc Public Health in Austria, and his FRCPC degree at the Royal College in Ottawa. Dr. Sergi’s specialty areas of interest are congenital heart disease and metabolic diseases, carcinogenesis (bone/soft tissue/liver) and mitochondrial DNA‐related cardiomyopathies.

sergi@ualberta.ca
Autophagy rpacdd_ebm_Zhang-xianbin_001 Zhang Xianbin Department of General Surgery Shenzhen University General Hospital Shenzhen China

Dr. Zhang is currently a senior researcher and a resident in the Department of General Surgery,Shenzhen University General Hospital. He obtained his MD at Rostock University with great distinction. He mainly focuses on investigating how autophagy is involved in the chemoresistance of pancreatic cancer. Dr. Zhang currently published more than 30 publications and these publications have accumulated over 100 citations.

xianbin.zhang@szu.edu.cn
Frontiers Section Editors rpacdd_ebm_amin_001 Amin Amr Biology Department United Arab Emirates University Al-Ain UAE

Amr Amin has completed his PhD at University of Illinois at Chicago, and received a post-doctoral training in the field of molecular genetics at the University of Pennsylvania School of Medicine. He started his academic career at UAE University where he serves now as a Full Professor of Cell Biology. Amr’s research focuses on ways to control cancer, particularly liver cancer. He published many research articles and reviews and serves as reviewer and as an editorial member of many specialized peer-reviewed journals. He is also a member of many specialized societies and the sole recipient of national and international scientific awards.

a.amin@uaeu.ac.ae
rpacdd_ebm_dou-qp_002 Dou Qingping P. Departments of Oncology, Pharmacology and Pathology School of Medicine Wayne State University Detroit MI USA

Dr. Q. Ping Dou is Professor of Oncology, Pharmacology and Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI. He obtained his Ph.D. degree in chemistry from Rutgers University, and postdoctoral training at Dana-Farber Cancer Institute and Harvard Medical School. Dr. Dou has extensive experience in the fields of molecular targeting, drug discovery, chemoprevention, natural products, proteasome inhibitors, cell cycle and apoptosis, and has published ~231 peer-reviewed research and review articles, many of those in journals of the highest quality. Dr. Dou is also an inventor of multiple US and international patents.

doup@karmanos.org Molecular Targets for Cancer
rpacdd_ebm_kwok-hf_001 Kwok Hang F. Faculty of Health Sciences University of Macau Macau

Prof. Hang Fai (Henry) Kwok currently holds the positions of Associate Professor and Consultant of Histopathology Core in the Faculty of Health Sciences at the University of Macau. He also serves as a Visiting Scientist in the CRUK Cambridge Institute at the University of Cambridge. His research interests focus on protease and venom biochemistry with biologics development to pursue novel therapeutic, prognostic, and diagnostic approaches in the treatment of cancer. Prof. Kwok has authored over 65 research and review articles. Dr. Kwok is also an inventor of multiple international patents, and currently serves as member of editorial board/guest editor in four international journals.

hfkwok@umac.mo Antibodies and Peptides in Cancer Therapy
rpacdd_ebm_shtil_001 Shtil Alexander Blokhin Cancer Center Moscow Russia

Dr. A. Shtil received his MD degree in Orenburg State Medical Institute and PhD in Moscow Research Institute of Otorhinolaryngology. In 1994-2002 he worked in the University of Illinois at Chicago, Lee Moffitt Cancer Center and Sloan-Kettering Cancer Institute, studying the mechanisms of multidrug resistance and altered drug response in cancer (with I.Roninson, W.Dalton and K.Scotto). After returning to Blokhin Cancer Center he established a new laboratory of tumor cell death with broad interests in cancer biology. The laboratory is studying the molecular mechanisms of cytocidal effects of small molecular weight compounds as perspective anticancer drug candidates. Our particular interest is novel DNA ligands, including the derivatives of anthraquinone and porphyrins that target the double helix and complex DNA structures. We also investigate the anti-apoptotic and pro-proliferation protein kinase Pim-1, the druggable target for newly developed indole based inhibitors. International cooperation includes the European Consortium “Protein kinases – Novel Drug Targets of Post Genomic Era” and contacts with grroups in the United States, France, Japan and Taiwan. Dr. Shtil has authored 150 scientific papers, review articles and a number of patents. He is member of editorial boards in four international journals.

shtilaa@yahoo.com Molecular Responses to Anticancer Drugs
rpacdd_ebm_wang-w_001 Wang Weiguang Faculty of Science and Engineering University of Wolverhampton Wolverhampton WV1 1LY UK

Dr. Wang is a Professor of Experimental Cancer Therapeutics in University of Wolverhampton, UK and Director of Disulfican Ltd. His research interests are focused on study of cancer cell chemoresistance. He is interested in the relationship between hypoxia-triggered NF-κB pathway activation, cancer stem-like cells and de novo/acquired chemoresistance. His group has been trying to identify some clinically available medicine with inhibiting effect on NF-κB pathway and cancer stem-like cells to target cancer cells and and sensitise cancer cells to conventional anticancer drugs. Dr Wang has more than 100 publications and several patents in anticancer drug development.

w.wang2@wlv.ac.uk Cancer Stem Cells and Chemoresistance
Book Review Editor rpacdd_ebm_Orlov_001 Orlov Sergei N. Department of Medicine Laboratory of Biomembranes Lomonosov Moscow State University Moscow Russia

Dr Sergei N. Orlov received his PhD degree in 1975 in Biophysics at Lomonosov Moscow State University, Russia In 1983, he got his second PhD in Physiology at the National Academy of Science, Minsk, Belarus Republic. In 1989 he was appointed as Professor and Chair, Department of Biomembranes, Faculty of Biology, Lomonosov Moscow State University, Russia. Since 1990 he has held visiting professorships in many universities. His current research interest aimed at the relative impact of cell volume changes and intracellular monovalent ions in regulation of gene expression, cell proliferation and apoptosis and their implications in the pathogenesis of cardiovascular, kidney and lung disorders.

sergeinorlov@yandex.ru sergei.n.orlov@umontreal.ca
Editorial Board Members rpacdd_ebm_Ahmadi-sh_001 Ahmadi Amirhossein Faculty of Pharmacy Mazandaran University of Medical Sciences Sari Iran

The experienced researcher with a demonstrated history of researching in the field of pharmaceutical sciences. Skilled in clinical research, Animal models, Cellular models, Scientific writing & publishing. He has focused on extensive fields of Pharmacology & Toxicology, Natural products, Radiopharmaceuticals, Nanomedicine, Radiation biology, Cancer chemoradiotherapy and other fields of Pharmacy at the Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran. He has published many originals and reviews in high-quality journals and selected as a recognized international editor and peer reviewer by famous publishers. In 2019, Dr. Amirhossein Ahmadi certificates for placing in the top 1% of reviewers in Cross-Field on Publons global reviewer database.

amirhossein_pharma@yahoo.com
rpacdd_ebm_almerico-am_001 Almerico Anna M. Department Farmacochimico, Tossicologico e Biologico University of Palermo Palermo Italy

Anna Maria Almerico graduated in chemistry with full marks and honours in 1977 (University of Palermo). During her academic career, she was visiting Professor at the School of Chemical Sciences, UEA (UK, 1983–1984), at the College of Pharmacy – OSU (USA, 1986–1987), at Masaryk University – Brno (Czech Republic, 1993). Currently she is Full Professor of Medicinal Chemistry at the University of Palermo. Her scientific interests are mainly devoted to the design, synthesis and evaluation of biological properties of new heterocyclic compounds related to well-known anticancer/antiviral/antiparasitic drugs. She is coauthor of more than 130 papers and 160 communications to Congresses.

annamaria.almerico@unipa.it
rpacdd_ebm_aneja-r_001 Aneja Ritu Department of Biology Georgia State University Atlanta GA USA

Ritu Aneja is a Professor of Cancer Biology at Georgia State University where she is also the Director of Graduate Studies in Biologyand Director of the Molecular Basis of Disease(MBD) Program that fosters interdisciplinary research. She has published over 125 papers in peer-reviewed journals and has presented more than 50 invited talks at various prominent forums in the US, China, India, Africa, and Europe. Two years ago, sheco-founded the International Consortium for Advancing Research on Triple Negative Breast Cancer (ICART; www.theicart.org)with the vision of revitalizing research focused on this understudied, highly aggressive and complex subtype of breast cancer.

raneja@gsu.edu
rpacdd_ebm_arcaro_001 Arcaro Alexandre Department of Clinical Research Bern University Hospital Bern Switzerland

Alexandre Arcaro is a group leader at Bern University Hospital in Switzerland. He graduated in biology at the University of Lausanne (Switzerland) in 1992 and obtained a Ph.D. in natural sciences from the University of Fribourg (Switzerland) in 1995. He was then a postdoctoral fellow at the Ludwig Institute for Cancer Research, University College London, United Kingdom, from 1996 to 1997 and at the Ludwig Institute for Cancer Research, Lausanne Branch, from 1998 to 2000. From 2000 to 2003 he was then a lecturer at Imperial College Faculty of Medicine, London, United Kingdom. He was a group leader at the University Children’s Hospital Zurich, Switzerland, from 2003 to 2009. His research work is focused on the study of receptor tyrosine kinase signaling and PI3K isoforms in human cancer.

alexandre.arcaro@dkf.unibe.ch
rpacdd_ebm_Samani_001 Asadi-Samani Majid Medical Plants Research Center, Basic Health Sciences Institute Shahrekord University of Medical Sciences Shahrekord Iran

Dr. Majid Asadi-Samani completed his Ph.D. in Biomedical Sciences (Medical immunology). As a researcher, he has worked at the Cellular and Molecular Research Center and the MedicalPlants Research Center of Shahrekord University of Medical Sciences, he completed his research around some desired issues especially in biomedical sciences, phytomedicine, pharmacognosy, cancer research, and immune responses. He has published more than 200 scientific papers in peer review international journals and presented his works in more than 20 national and international congresses. Currently, He is working as a faculty member at the Basic Health Sciences Institute of Shahrekord University of Medical Sciences. His research focuses on the effects of medicinal plants and their derivatives to discover new anticancer drugs to prevent and treat cancer especially breast cancer and prostate cancer. Besides, after the onset of the COVID pandemic, he has evaluated the seroprevalence of the disease and has been studying COVID-19 with immunological approaches.

biology_2011@yahoo.com
rpacdd_ebm_Asker-sh_001 Asker Mohsen Orcid Microbial Biotechnology Department National Research Center Cairo Egypt 0000-0003-4321-0625 24437660400 mohsenmsa@yahoo.com Bateman Andrew Research Institute of McGill University Health Centre Montreal QC Canada

Professor Andrew Bateman got his PhD degree from Imperial College of Science and Technology, University of London, UK in 1985. He is affiliated with the Research Institute of McGill University Health Centre, Montreal, Quebec, Canada. His main expertise lies in areas/fields of peptide, cell biology, cancer biology, cancer research, endocrinology, peptide chemistry, proteins, etc. Prof. Bateman has published more than 75 articles in various journals of international repute, accumulating more than 5,530 total citations.

andrew.bateman@muhc.mcgill.ca
rpacdd_ebm_bishayee-a_001 Bishayee Anupam Department of Pharmaceutical Sciences Larkin University Miami FL USA

Dr. Bishayee received a Bachelor of Pharmacy, Master of Pharmacy, and Ph.D. (Pharmacy) from Jadavpur University, Kolkata, India. Dr. Bishayee performed post-doctoral research at Rutgers University, Newark, New Jersey (formerly University of Medicine and Dentistry of New Jersey) and completed a fellowship in Academic Medicine from Northeast Ohio Medical University. Dr. Bishayee’s primary research interest during last two decades encompasses cancer biology, cancer therapeutics, and cancer prevention. Dr. Bishayee is serving as Editor-in-Chief of the Journal of Natural Products in Cancer Prevention and Therapy as well as editorial board member and reviewer of more than 60 reputed journals.

Anupam.Bishayee@cnsu.edu abishayee@auhs.edu, abishayee@gmail.com, abishayee@lecom.edu
Blanco Ignacio Genetic Counselling Unit Catalan Institute of Oncology Barcelona Spain

Dr. Ignacio Blanco got his PhD degree from University of Nebraska Medical School, Omaha, Nebraska, USA. He is affiliated with the Genetic Counselling Unit, Catalan Institute of Oncology, Barcelona, Spain. His main expertise lies in the areas/fields of prenatal diagnosis, hereditary cancer, human genetics, cancer genetics, etc. Dr. Blanco has published more than 175 articles in various journals of international repute, accumulating more than 11,335 total citations.

Ignacio.blanco.guillermo@gmail.com iblanco.germanstrias@gencat.cat
Bussolati Benedetta Department of Internal Medicine University of Turin Torino Italy

Dr. Benedetta Bussolati obtained her medical degree from the University of Torino, Italy, and her PhD in Physiopathology of the Renal Insufficiency from the University of Parma, Italy. She currently holds the position of Associate Professor of Nephrology at the University of Torino and Director of a Research group at the Molecular Biotechnology Centre. Her research interests mainly lie in the areas/fields of angiogenesis, regenerative medicine, extracellular vesicles, stem cells, renal regeneration, etc. Dr. Bussolati has published more than 180 articles in various journals of international repute, accumulating more than 13,960 total citations.

benedetta.bussolati@unito.it
rpacdd_ebm_camphausen-k_001 Camphausen Kevin Radiation Oncology Branch National Cancer Institute MD USA

Kevin Camphausen received his undergraduate degree from Purdue University in 1988.  He then completed his MD (1996) and medical internship (1997) at Georgetown University Medical Center.  He next completed his residency in Radiation Oncology at the Joint Center of Radiation Therapy at Harvard Medical School (2001).  While there, he worked in the laboratory of Dr. Judah Folkman studying the interactions of antiangiogenic therapy and radiotherapy.  He joined the Radiation Oncology Branch in 2001 as a tenure track investigator, received tenure in 2007 and was promoted to Chief of the Radiation Oncology Branch (ROB), Center for Cancer Research (CCR), NCI.  He is an internationally recognized expert in the field of drug-induced tumor radiosensitization.

camphauk@mail.nih.gov
Caraglia Michele Department of Biochemistry, Biophysics and General Pathology Second University of Naples Naples Italy

Prof. Michele Caraglia obtained his medical degree from University of Campania "L. Vanvitelli", Naples, Italy. Prof. Caraglia is affiliated with the Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy. His research activities are focused on cancer research with particular interest on micro-RNAs as both therapeutics and diagnostics, and on the delivery of anti-cancer agents in tumours through the use of nanocarriers. Prof. Caraglia has published more than 500 articles in various journals of international repute, accumulating more than 18,625 total citations.

michele.caraglia@alice.it michele.caraglia@unina2.it
Cerqueira Nuno Chemistry Department University of Porto Porto Portugal

Dr. Nuno Cerqueira obtained his Ph.D. degree in 2007 in Chemistry from University of Porto, Porto, Portugal. Dr. Cerqueira is affiliated with the Chemistry Department, University of Porto. His areas/fields of primary research include Drug Discovery, Computational Chemistry, Quantum Mechanics, Enzymes, Proteins, Bioinformatics, Biotechnology, Biochemistry, etc. Dr. Cerqueira has published more than 90 articles in various journals of international repute, accumulating more than 2,250 total citations.

nscerque@fc.up.pt
Chen Fener Department of Chemistry Fudan University Shanghai P.R China

Dr. Fener Chen obtained his Ph.D. degree in 1999 (in Organic Chemistry) from Sichuan University, Chengdu, China. Dr. Chen is affiliated with the Department of Chemistry, Fudan University, Shanghai, China. His areas/fields of primary research activities include: (1) Asymmetric Total Synthesis of Natural Products and Drugs; (2) Development of Novel Asymmetric Reactions and Their Applications in Chiral Drug Synthesis; (3) Molecular Design, Synthesis and Structure-Activity Relationship Studies of Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors Base on CADD and Mechanisms. Dr. Chen has published more than 310 articles in various journals of international repute, accumulating more than 4,060 total citations.

rfchen@fudan.edu.cn
rpacdd_ebm_Chen-Haixia-sh_001 Chen Haixia Orcid School of Pharmaceutical Science and Technology Tianjin University Tianjin China 0000-0002-2596-9622

Dr. Haixia Chen is a Professor at the School of Pharmaceutical Science and Technology in Tianjin University. She has brought forth new ideas on the investigation of bioactive natural constituents and achieved many research achievements on the isolation, preparation and identification of the natural products, activity screening and efficacy evaluation, pharmacology and toxicology of the natural products. She has had more than 18 research fundings as PI, more than 120 publications in highly prestigious international journals and various presentations in both national and international conferences. She has 8 books published, 40 Chinese patents applied and 21 of them were authorized. She has been serving as an editorial board member of many international journals.

chenhx@tju.edu.cn
Chieffi Paolo Department of Experimental Medicine Second University of Naples Naples Italy

Dr. Paolo Chieffi obtained his PhD degree in Comparative Endocrinology from University of Padua, Padua, Italy. Dr. Chieffi is affiliated with the Department of Experimental Medicine, Second University of Naples, Naples, Italy. His research expertise focuses on Cell signaling, Cancer biology, Western blot analysis, Molecular cell biology, Immunohistrochemistry, Immunofluorescence, Molecular biology, Cell culture, PCR, Proteins, etc. Dr. Chieffi has published more than 100 articles in various journals of international repute, accumulating more than 3,230 total citations.

paolo.chieffi@unina2.it
rpacdd_ebm_cocco_001 Cocco Lucio Department of Anatomical Sciences University of Bologna Bologna Italy

Dr. Cocco is M.D. from the University of Chieti, School of Medicine. After being Visiting Scientist at the Beatson Inst. Cancer Res., Glasgow and at the AFRC Babraham Institute, Cambridge, U.K. is presently Professor, Chair of Anatomy and Head of Cellular Signalling Laboratory at the University of Bologna. Editorial Board: Advances in Biological Regulation Editor-in-Chief of Advances in Biological Regulation, is Board Member of Recent Patents on Anti-Cancer Drug Discovery, Cellular Signalling, Journal of Cellular Biochemistry Founder and First Co-Chairman of the new series of Gordon Research Conference “Signal Transduction Within the Nucleus” He has authored more than 300 full length papers in peer reviewed Journal and has discovered the nuclear signalling via inositol lipid cycle

lucio.cocco@unibo.it
rpacdd_ebm_via_001 Dalla Lisa V. University of Padova Padova Italy

Dr. Dalla Via obtained the degree in Biological Sciences with full marks cum laude and a doctorate (Ph.D.) in Biochemistry and Biophysics from the University of Padova, Italy. Currently Dr. Dalla Via is associate professor in the Department of Pharmaceutical and Pharmacological Sciences of the University of Padova. She has published 96 scientific publications.

lisa.dallavia@unipd.it
rpacdd_ebm_entschladen-f_001 Entschladen Frank MetaVi Labs Witten Germany

Dr. Entschladen studied Biology at the University of Aachen, Germany, and obtained a doctorate in natural sciences at the Witten/Herdecke University, Germany. Dr. Entschladen has more than 20 years of research experience in oncology and published over 70 scientific publications. Currently, Dr. Entschladen is patent manager at the technology transfer agency PROvendis, Germany, and Adjunct Professor at the Witten/Herdecke University. In addition, Dr. Entschladen is co-founder of MetaVì Labs, Austin, TX.

entschladen@uni-wh.de Frank.Entschladen@uni-wh.de
rpacdd_ebm_esposito-f-sh_001 Esposito Francesco Orcid Federico II University of Naples Naples Italy 0000-0002-7709-5736

Francesco Esposito graduated in Medical Biotechnology in 2005 at the University of Naples "Federico II", carrying out his thesis at the Dipartimento di Biologia e Patologia Cellulare e Molecolare "L. Califano". In 2009 he discussed his PhD thesis and got PhD in Molecular Oncology and Endocrinology, at the Dipartimento di Biologia e Patologia Cellulare e Molecolare "L. Califano ", University of Naples "Federico II". From 2009 to 2011, Dr. Esposito continued his research with a post-doctoral fellowship granted by the FIRC. From May 2013, Dr. Esposito is a researcher at the CNR-IEOS.

francesco.esposito2@unina.it
Estrov Zeev Department of Leukemia University of Texas MD Anderson Cancer Center Houston, TX USA

Dr. Zeev Estrov received his M.D. degree (with honors) in 1975 from the Tel-Aviv University School of Medicine, Tel Aviv, Israel. Dr. Estrov is affiliated with the Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. His research has been primarily focused on the biology and pathobiology of normal and neoplastic hematopoietic cells. Dr. Estrov has published more than 515 manuscripts in various journals of international repute, accumulating more than 29,970 total citations.

zestrov@mdanderson.org
Franklin Richard A. Department of Microbiology and Immunology Brody School of Medicine at East Carolina University Greenville NC USA franklinr@ecu.edu Fritz Gerhard Institute of Toxicology Heinrich Heine University Düsseldorf Düsseldorf Germany fritz@uni-duesseldorf.de rpacdd_ebm_fu-l_001 Fu Liwu Department of Experimental Research (Cancer Institute) Sun Yat-sen University Guangzhou China

Dr. Fu received Ph. D. degree from Sun Yat-sen University in 1996 and later on becamea professor there. He also stayed in Medical University of South Carolina as postdoctoral fellowship(1999- 2001). His active research fields includereversal multidrug resistance induced by ABC transporters, new drug research and development for treatment of cancer patients, primary cancer tissue culture and test of drug sensitivity for personalized chemotherapy. He is Chairman of Board of Directors, Guangdong Anticancer Society; Associate Director of Cancer Pharmacology and Chemotherapy Section, Chinese Pharmacological Society, Anticancer Drug Section, Chinese Anticancer Society; Active Member of AACR; Member of Board of Directors, Guangdong Pharmacological Society and Chinese Pharmacological Society.

fulw@mail.sysu.edu.cn
Fulda Simone Institute for Experimental Cancer Research in Pediatrics Goethe-University Frankfurt Frankfurt Germany

Since 2010 Prof. Dr. Simone Fulda is the Director of the Institute for Experimental Tumor Research in Pediatrics, which is part of the Dr. Petra Joh Research House of the Frankfurt Foundation for Children with Cancer. She studied medicine in Cologne, at Harvard Medical School in Boston, the University of California in San Francisco, the University of Arizona and University College Dublin. After the state examination and doctorate in 1995, she worked as a postdoc at the German Cancer Research Center and at the Institute Gustave Roussy in Villejuif. The specialist examination and her habilitation in paediatrics took place in 2001. From 2002 to 2007, she received a Heisenberg scholarship and from 2007 to 2010, held a DFG research professorship. In 2012, she was appointed to the Science Council. Her H index is 80

simone.fulda@kgu.de
rpacdd_ebm_Galanski_001 Galanski Mathea Sophia Institute of Inorganic Chemistry University of Vienna Vienna Austria

Prof. Dr. Galanski received a doctorate (Ph.D.) in Chemistry from the University of Heidelberg, Germany. She holds the position of Associate Professor at the Institute of Inorganic Chemistry of the University of Vienna, Austria. Dr. Galanski has (co)authored more than 150 publications in the field of bioinorganic chemistry with focus on the development of platinum-based anticancer drugs.

markus.galanski@univie.ac.at
Grieb Pawel Department of Experimental Pharmacology Mossakowski Med. Res. Ctr. Polish Acad. of Sci Warsaw Poland pgrieb@imdik.pan.pl rpacdd_ebm_Han-l-sa_001 Han Lei Orcid Department of Neurosurgery Tianjin Medical University Tianjin China 0000-0002-0707-5027

The Han lab is focused on how the activities of hundreds or even thousands of kinase or lncRNAs are coordinated to achieve biological meaning. We have pioneered methods to predict, dissect, and control large-scale gene regulatory network; these methods have provided insights into human cancer, and other disease. A particular interest is targeting delivery the drugs to the tumor region, particularly with the help of nanoparticles.

superhanlei@hotmail.com
He Tong Chuan Department of Surgery The University of Chicago Medical Center IL USA

Tong-Chuan He has been the Associate Professor of Orthopedic Surgery and Rehabilitation Medicine, at the University of Chicago in the Department of Orthopedic Surgery and Rehabilitation Medicine, Chicago IL. His research interests are in BMP signaling, Bone and skeletal biology, Bone and soft tissue tumors, Cancer drug resistance, Cancer metastasis, Gene/cell-based therapy, Mesenchymal Stem Cells, Noncoding RNAs, Regenerative medicine, Wnt signaling. He directs the Molecular Oncology Laboratory in the Department of Orthopaedic Surgery and Rehabilitation Medicine. His lab comprises a dynamic group of basic science investigators and physician scientists, who have diverse expertise and a broad range of research interests. He did Postdoc in Cancer Biology/Genetics in 1999 from HHMI/Johns Hopkins School of Medicine Baltimore, MD. He did PhD in Molecular Cell Biology in 1994 from The Pennsylvania State University Park, PA. He has been an author of 301 papers with 30376 Citations by 23027 documents. He has an h-index of 76.

tche@surgery.bsd.uchicago.edu t_c_he@yahoo.com, tche@uchicago.edu, tche@bsd.uchicago.edu
rpacdd_ebm_Ho_001 Ho John W. The Chinese University of Hong Kong Shatin Hong Kong

Professor Wing Shing (John) Ho, Ph.D., is an associate professor in the Biochemistry Programme of School of Life Sciences at The Chinese University of Hong Kong. He obtained a B.S. from The University of Alberta, and M.A., and a Ph.D. in Biological Chemistry (1985) from State University of New York at Buffalo. After completing a post-doctoral training in Pediatrics Department at SUNYAB and University of Utah. He was appointed associate professor in the School of Life Sciences at The Chinese University of Hong Kong in 1994.

ws203ho@cuhk.edu.hk
Hu Wei Department of Gynecologic Oncology and Reproductive Medicine University of Texas MD Anderson Cancer TX USA

Wei Hu, M.D., Ph.D. has been associated with M.D. Anderson Cancer Center since 1994. She is currently an Associate Professor in the Department of Gynecologic Oncology at MDACC. Dr. Hu received her Medical degree in 1986 and her Ph.D. in 1993 from the Tongji Medical University, Huazhong University of Science and Technology. She received her Postdoctoral training during 1994-1997 from the University of Texas M.D. Anderson Cancer Center in the Department Gynecologic Oncology and Cellular Oncology. Dr. Hu's main research interests are focused on the areas of targeting epigenetic abnormalities and tumor environment in VEGF-resistant ovarian cancer, and RNA interference based-treatment. Dr. Hu is the principal and co-investigator for several translational and preclinical studies which have been supported by peer-reviewed resources and private industries. She has published numerous peer-reviewed and invited review articles and co-authored several book chapters. In 2009, she began collaborating with Dr. Anil K Sood on various basic and translational projects and she has been under his direct supervision. She has several joint publications with Dr. Sood and she functions as a Co-Investigator with him on several funded projects. Dr. Hu serves on the editorial board for several journals and has been a reviewer for journals. She is an Adjunct Faculty Member at The University of Texas Graduate School of Biomedical Sciences at Houston. She is an active member of the American Association of Cancer Research.

weihu@mdanderson.org
rpacdd_ebm_h-s-huang_001 Huang Hsu-Shan Department of Pharmacy Practice Taipei Medical University Taipei Taiwan

Dr. Huang obtained a doctorate (Dr. rer. nat.) in Pharmacy from the University of Regensburg, Germany. Dr. Huang was former dean of School of Pharmacy, and head of the Department of Research and Development in NDMC and director of Department of Pharmacy Practice, Tri-Service General Hospital/NDMC. Currently Dr. Huang is a Professor in College of Medical Science and Technology, Taipei Medical University also an Adjunct Professor in NDMC. He has published more than 90 scientific publications and is a named inventor of 30 issued U.S and Taiwan patents.

Dr. Huang is currently the Editorial Advisory Board of this journal, published by Bentham Science Publishers.

huanghs99@gmail.com huanghs99@gmail.com, huanghs@mail.ndmctsgh.edu.tw, hsh411135@yahoo.com.tw, hsh411135@yahoo.com
rpacdd_ebm_hung-h_001 Hung Huynh Division of Cellular and Molecular Researh National Cancer Centre of Singapore Singapore

Prof. Huynh is an adjunction professor at McGill University, Montreal, Canada and National University Singapore. He is also the Principal Investigator of Laboratory of Molecular Endocrinology at National Cancer Centre since 1999. His research interest is to establish and developthe xenograft models of human solid malignancies: Hepatocellular carcinoma, Gastrointestinal Stromal Tumours, Gastric Cancer, Lung Cancer, Pancreatic Cancer, Breast Cancer, Ovarian Cancer, NPC and Head and Neck cancers from patient’s tumor specimens. He has published as the first or corresponding author in around 125 peer-reviewed journals and has collaborated with various pharmaceutical companies and academic institutions to identify novel treatments.

cmrhth@nccs.com.sg
Inoue Ken-Ichiro Centre for Medical Science International University of Health and Welfare Otawara Japan kinoue@iuhw.ac.jp rpacdd_ebm_keisari-y_001 Keisari Yona Department of Clinical Microbiology and Immunology Tel Aviv University Tel Aviv Israel

Dr. Keisari obtained Ph.D. and M.Sc. degrees at the faculty of life sciences, Tel Aviv University. He is member of the Dept. of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Israel, since 1979 and is Prof. Emeritus since 2015. Dr. Keisari is co-author of 88 peer reviewed scientific papers, 6 reviews, 5 chapters in books, edited 2 books, and one patent. He serves as member of editorial board of 6 journals. Dr. Keisari is one of the founders and past president of the “Israeli Society for Cancer Research” (ISCR), and serves as the treasurer of the “International Cancer Microenvironment Society”. He also serves as the Chief Biomedical Officer of Alpha Tau Medical.

ykeisari@tauex.tau.ac.il
cmp_ebm_khan-h-ah_001 Khan Haroon Orcid Department of Pharmacy Abdul Wali Khan University Mardan Pakistan 0000-0002-1736-4404 https://scholar.google.com.pk/citations?user=R4X2im8AAAAJ&hl=en http://haroonkhan.awkum.edu.pk

Dr. Khan is the full Professor at the Department of Pharmacy, Abdul Wali Khan University Mardan (AWKUM), Pakistan. In 17 years of professional experience, he has significantly contributed to the teaching and training of pharmacy graduate and pharmacy-related services. Dr. Khan remained the member of AWKUM syndicate, executive member of Pharmacy council of Pakistan(KP), and editorial member of more than 10 journals including Phytomedicine, Food and Chemical toxicology, and Metabolic Brain Disease. He is the author of more than 200 articles including editorial, review, research, and four books including one by Elsevier. Moreover, several post- graduate scholars are working under his supervision.

hkdr2006@gmail.com haroonkhan@awkum.edu.pk
Khan Michael Department of Biological Sciences, Molecular Medicine Biomedical Research Institute Coventry UK

Michael Khan has been the Executive Director at Silence Therapeutics PLC since 2013. He joined the RNAi therapeutics company, initially as an NED and advisor in 2012 and then invited to become CMO and Executive Director later that year. He has contributed to three successful fund-raising campaigns. He has been an invited speaker at several industry events/conferences. He has over 30 years of clinical experience, including 17 years as a senior NHS consultant physician and clinical academic, in general medicine, diabetes and endocrinology. Has expertise and experience in translational research, decision making and strategic planning in industry. Has facilitated development of new clinical trials in HNSCC, a preclinical programme in preeclampsia and a drug delivery programme for ODN using conjugation chemistry. He made a substantial contribution, for over 2 years, to develop and write the new NICE guideline (CG181) on Lipid-lowering drugs and assessment of cardiovascular risk. He has been a highly cited researcher with over 100 publications across basic science and clinical medicine including in Cell, Nature, BMJ and Lancet, has under 3000 citations, with an H-factor of 18. He has been a member of the Senior Management group for the Department of Biological Sciences from 2002-2006. Founder member and advisory board for the Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM). He was a grant reviewer and research analyst with extensive experience of reviewing large multi-million euro grants for the EC; Marie Curie, ITNs, STREPS, NoEs, IPs, from FP5 through to Horizon 2020. Besides, he has been a frequent reviewer for scientific journals.

Michael.Khan@warwick.ac.uk
rpacdd_ebm_kim-yh_001 Kim Hong Y. Department of Internal Medicine Korea University Anam Hospital Cancer Center Seoul South Korea

Yeul Hong Kim, MD, PhD is Professor of Medical Oncology at the Korea UniversityCollege of Medicine. He is certified in internal medicine and medical oncology by the Korean Association of Internal Medicine.

Dr. Kimis actively involved in the Cancer Genomic research for lung and gastrointestinal cancers using circulating tumor DNA.He currently is theChairman of Board, the Korean Cancer Association and President of Asian Clinical Oncology Society. Currently he is Director of the K-MASTER Cancer Precision Medicine Diagnosis and Treatment Enterprise, which is funded from Korea Ministry of Health and Welfare.

yhk0215@korea.ac.kr
Kim Sang G. College of Pharmacy Seoul National University Seoul Korea sgk@snu.ac.kr Kozlov Serguei V. Center for Advanced Preclinical Research National Cancer Institute Frederick MD USA

Serguei Kozlov, Ph.D., MBA, PMP is the Principal Scientist, Preclinical Technology and Optimization Team Leader at the Center for Advanced Preclinical Research Frederick National Laboratory for Cancer Research. He has expertise in Molecular mechanisms of bi- and mono-allelic gene expression and gene functioning in normal vs. diseased tissues, analysis of diverse developmental signaling pathways and their implication for pathogenic state of adult tissues, design and construction of genetically and biologically engineered murine models for variety of diseases, including tissue degenerative syndromes, autoimmune and inflammatory diseases, ageing, and cancer. He was a Staff Scientist, at the Cancer and Developmental Biology Laboratory, National Cancer Institute at Frederick, a Research Fellow at the Cancer and Developmental Biology Laboratory, National Cancer Institute at Frederick, Training Fellow at the National Institute for Medical Research, Medical Research Council, London, England and a graduate Student in Molecular Neurobiology at the Institute of Biochemistry, University of Zurich, Switzerland.

kozlovse@mail.nih.gov
rpacdd_ebm_kriajevska-m_001 Kriajevska Marina Department of Cancer Studies and Molecular Medicine University of Leicester Leicester UK

Dr. Kriajevska obtained a doctorate (Ph.D.) in Biochemistry from the Moscow State University,Russia. Dr. Kriajevska isa Fellow of the Higher Education Academy and a Fellow in the Institute of Biomedical Science, UK. Currently Dr. Kriajevska is anHonorary Lecturer in the Leicester Cancer Research Centre (UK) and the Editorial Board memberfor Scientific Reports. Her research interest is in the field of cancer cell biology with a particular focus on the role of S100 proteins in control of the cytoskeletal rearrangements and cell motility during Epithelial Mesenchymal Transition.

mk108@le.ac.uk
Kumar Atul Medicinal and Process chemistry Division CSIR-Central Drug Research Institute Lucknow India dratulsax@gmail.com rpacdd_ebm_lacher-md_001 Lacher Markus D. BriaCell Therapeutics Corp. CA USA

Since July 2015, Dr. Lacher is the Head of Research & Development at BriaCell Therapeutics Corp., animmunotherapy-focused biotechnology company. Previously, he served as a Senior Clinical Scientist, R&D at Cesca Therapeutics, Inc., an autologous cell therapy company;as a Scientist at BioTime, Inc. and its subsidiary OncoCyte Corporation; and as Founder & CEO of T cell Therapeutics, Inc., an immuno-oncology company focused on bispecific antibodies for prostate cancer. Earlier in his career, Dr. Lacher conducted cancer research at the University of California, San Francisco (UCSF). He earned his Ph.D. in 2001 from theUniversity of Bern, Switzerland.

doublehelix.pb2k@gmail.com
Lawnicka Hanna Department of Immunoendocrinology Medical University of Lodz Lodz Poland hlawnicka@wp.pl rpacdd_ebm_leung-ch-sa_001 Leung Chung-Hang Institute of Chinese Medical Sciences University of Macau Taipa Macau duncanleung@um.edu.mo rpacdd_ebm_j-lin-sh_001 Lin Jun Department of Anesthesiology Stony Brook University Stony Brook NY USA

Dr. Jun Lin is a Professor at Stony Brook University Health Science Center and Cancer Center. Dr. Lin completed his medical education and M.Sc. in pharmacology at Sun Yat-sen University, China and hold a M.D. degree from University of the State of New York. He was awarded a PhD in Biomedical Science from Mount Sinai School of Medicine, New York. Dr. Lin is the Editor in Chief of the International Journal of Physiology, Pathophysiology and Pharmacology and a review board member of the journal of Cancers. His lab studies the effects of anesthetics on cancer metastasis and biology.

Jun.Lin@stonybrookmedicine.edu
rpacdd_ebm_cara-lcl_001 Lopez-Cara Carlota L. University of Granada Granda Spain

Luisa Carlota Lopez-Cara was born in Granada. 1999 Degree in Pharmacy, 2005 PhD in Pharmaceutical Sciences 2005-2009 Post-Doctoral Fellowship Department of Pharmaceutical Sciences of the University of Ferrara and Department of chemistry of Emory University. 2009- 2012. Researcher in Department of Medicinal and Organic Chemistry of University of Granada. 2012-today Associate Professor It was engaged in the study of bioactive molecules with antiproliferative and antiangiogenic effects. Actually her research interests concern the design, synthesis and SARs study of new molecules endowed with antiproliferative activity both in vitro and in vivo and in particular of the mechanism that lead to cell death. She is author of about 75 scientific papers in qualified peer review journals. She is holder of many Spanish and European patents concerning the antitumoral molecules.

lcarlotalopez@ugr.es
Lwaleed Bashir A. Department of Urology University of Southampton Southampton UK

Professor Bashir Lwaleed is a council member appointed by the Senate in 2015. An academic haematologist by profession, he is currently an Associate Professor in Health Sciences. He has studied or worked in four academic institutions in the UK, the last 24 years continuously at the University of Southampton. He gained a PhD in 1998 in Medicine from Southampton and was awarded the Fellowship of the Royal College of Pathologists (FRCPath) in 2008. With a wide ranging international expertise and experience in clinical academia and healthcare environments he is member of several professional and learned societies. He is a Fellow of the Institute of Biomedical Sciences, a Chartered Biologist and Fellow of the Society of Biologist, a Member of the British Society for Haematology and the British Society of Haemostasis and Thrombosis. He has also served on a number of national education and professional bodies, representing Faculty and University helping to shape national agendas on education, training and curriculum development including Modernising Scientific Careers Programmes and Council of Healthcare Science in Higher Education, etc. He served on the Health Sciences Board and currently sits on the Thrombosis Committee, Southampton University Hospitals as well as the Wessex Medical Research Scientific Advisory Committee. Bashir has developed and sustained major research activities of international reputation in the fields of diagnostic haematology and cancer therapy. His work has always aspired to clinical translation through influencing evidence-based practice or commercial product development. His recent research findings have featured at BBC-Online. He has served on editorial boards of over fifteen journals and has been an Editor for four peer-reviewed international journals.

bashir@soton.ac.uk
Mannello Ferdinando Department of Biomolecular Sciences (DISB) University "Carlo Bo" of Urbino Urbino Italy ferdinando.mannello@uniurb.it rpacdd_ebm_marques-mp_001 Marques Maria Paula Department of Life Sciences University of Coimbra Coimbra Portugal

Maria Paula Marques received her MSc in Physical-Chemistry (1987) her PhD (1995) from the Univ. Coimbra. M.P.M. Marquesis currentlya professor at the Dep. Life Sciences of the Univ. Coimbra, assistant-coordinator of the R&D Group “Molecular Physical-Chemistry” and head of the “Chemoprevention, -Therapy & -Toxicology” laboratory. M.P.M. Marques has authored 130 scientific papers, 8book chapters and co-edited 3 books. She is an affiliated member of the Royal Society of Chemistry and of the Clinical Infrared and Raman Spectroscopy for Medical Diagnosis (CLIRSPEC), the Portuguese delegate for the COST Action Raman4Clinics, an associate editor of RSC Advances.

pmc@ci.uc.pt
McKeage Mark J. Department of Pharmacology and Clinical Pharmacology The University of Auckland Auckland New Zealand

Professor Mark McKeage is a Medical Oncologist. He is a professor and physician-scientist at the University of Auckland in the Department of Pharmacology in Clinical Pharmacology, as well as Co-Director of the Auckland Cancer Society Research Centre. He also is a medical oncologist at Auckland City Hospital. After graduating in medicine from the University of Otago, Mark trained at Wellington Hospital and the Royal Marsden Hospital in London. He worked as a medical oncology staff specialist at Prince of Wales Hospital in Sydney before returning to New Zealand to his current position. Professor Mark McKeage has worked for many years as a medical oncologist specialising in the treatment of head and neck cancer, and lung cancer. He has published over 100 research articles and regularly gives lectures on topics related to cancer treatment. He leads a research group and an active programme of clinical research on lung cancer genetic testing, targeted therapies, and platinum-based anti-cancer drugs. His clinical practice is strongly underpinned by a scientific evidence-based approach to treatment recommendations. Mark is past-president and member of the New Zealand Society for Oncology, and member of the American Association for Cancer Research, the American Society for Clinical Oncology, the European Society for Medical Oncology, and the International Association for the Study of Lung Cancer.

m.mckeage@auckland.ac.nz
Messori Luigi Department of Chemistry University of Florence Sesto Fiorentino Italy

Luigi Messori is a Lecturer of general and inorganic chemistry. In particular, he has been involved in the study of the behavior in solution of various metalloproteins, mainly using nuclear magnetic resonance spectroscopy. Currently, he is interested in the role of metals in medicine, in particular in metal complexes with antitumor activity and their interactions with nucleic acids and proteins. He has expertise in Gold, Biochemistry and Inorganic Chemistry.

luigi.messori@unifi.it
rpacdd_ebm_Micheau_001 Micheau Olivier Facultes de Medecine et de Pharmacie INSERM Dijon France

Dr. Micheau studied molecular biology and obtained a Ph.D. in 1999 at the University of Bourgogne, Dijon, France. He moved the same year to Jürg Tschopp's laboratory at the department of biochemistry of the University of Lausanne, Switzerland, where he identified the molecular mechanisms underlying TNFR1 death signaling. In 2003 he was awarded a full tenured INSERM position at the University of Bourgogne-Franche-Comté in the Lipid Nutrition and Cancer department (LNC U866), and was appointed director of research in the INSERM unit U866 in 2015. His current research focuses on the characterization of TRAIL signaling.

omicheau@u-bourgogne.fr
rpacdd_ebm_mishra-v_001 Mishra Vijay School of Pharmaceutical Sciences Lovely Professional University Phagwara India

Dr. Vijay Mishra is an Associate Professor at School of Pharmaceutical Sciences, Lovely Professional University, Phagwara (Punjab), India. Dr. Mishra earned his doctoral degree in Pharmaceutical Sciences from Department of Pharmaceutical Sciences, Dr. H.S. Gour Central University, (MP), India. He has been a recipient of several internationally acclaimed fellowships and awards. He has authored more than 40 international publications in reputed journals, 4 book chapters, 3 books and 2 patents (filed). He is serving as a reviewer and Editorial Board Member of various journals of high repute. He is a life member of Indian Science Congress, Kolkata, India. His current research interests encompass cancer, nanomedicine, toxicology, surface-engineered dendrimers, carbon nanotubes, quantum dots, carbon dots, siRNA delivery.

vijay.20352@lpu.co.in vijaymishra2@gmail.com
rpacdd_ebm_Mocellin_001 Mocellin Simone Department of Experimental Medicine and Immunotherapy University of Padova Padova Italy

Prof. Simone Mocellin obtained his MD degree at the University of Padova, where he specialized in General Surgery in 1998 and he's got a PhD doctorate in Surgical Oncology in 2002. For two years (1999-2001) he worked at the Surgery Branch of the National Cancer Institute of Bethesda (Maryland, USA). Currently he works as consultant surgeon at the Surgical Oncology branch of the Istituto Oncologico Veneto (IOV-IRCCS) of Padova, Italy. He is also professor of surgery at the Dept. Surgery Oncology and Gastroenterology of the University of Padova, Italy. He is the author of more than 160 articles published in peer-review international medical journals. His main interest is surgical oncology with special regard to the surgical treatment and translational research in the fields of cutaneous melanoma, soft tissue sarcomas and gastrointestinal cancers.

mocellins@hotmail.com simone.mocellin@iov.veneto.it
rpacdd_ebm_mollinedo_001 Mollinedo Faustino Institute of Molecular and Cellular Biology of Cancer Cancer Research Center CSIC-University of Salamanca Salamanca Spain

Faustino Mollinedo received his Ph.D. in Chemistry in 1982 (Complutense University, Madrid). He then moved to Dartmouth Medical School in Donald L. Schneider’s laboratory (1982-3), where they identified a novel cytoplasmic granule (tertiary granule) in human neutrophils, and then to New York University Medical Center. In 1986 he obtained a tenure position at the Spanish National Research Council, establishing successively his laboratory in Madrid, Valladolid and Salamanca. Now he has moved to the Center for Biological Research in Madrid (2016). His laboratory has made several important contributions in neutrophil biology, ether lipids’ mechanism of action, and apoptosis as a target in cancer therapy. His laboratory identified the translocation of Fas/CD95 death receptor into lipid raft membrane domains as a new mechanism of apoptosis regulation, unveiling rafts as a new target in cancer therapy.

fmollin@usal.es
rpacdd_ebm_moreau_001 Moreau Pascale Clermont Auvergne University Clermont-Ferrand Institute of Chemistry Clermont-Ferrand France

Prof. Pascale Moreau obtained a Master Degree in Biophysicochemistry and Cellular and Molecular Biology, and a Ph.D in Chemistry and Physicochemistry of Compounds with Biological Interest, from the University of Orléans (France). She joined Pr. Victor A. Snieckus’s group at Waterloo University (Canada), working on macrocycles synthesis and directed ortho-metalation. During a second post-doctoral position at Bristol-Myers-Squibb (Marne-la-Vallée, France) she focused on asymmetric synthesis. In 1996, she moved to Blaise Pascal University (Clermont-Ferrand, France) working on hemisynthesis of rebeccamycin derivatives. Her current research is devoted to the development of new bioactive heteroaromatic compounds.

http://iccf.univ-bpclermont.fr/spip.php?rubrique44&lang=en

pascale.moreau@univ-bpclermont.fr pascale.moreau@uca.fr
rpacdd_ebm_nam_001 Nam Jeong-Seok School of Life Sciences Gwangju Institute of Science and Techonology Gwangju Korea

Dr. Jeong-Seok Nam obtained a doctorate (Ph.D.) in Veterinary Medicine from Seoul National University, Seoul, South Korea. Dr. Nam's research focuses on understanding and targeting cancer metastasis. He is working as an associate professor in school of life sciences, Gwangju Institute of Science and Technology, Gwangju, South Korea. He has published more than 80 scientific publications. He is currently the editorial board member of this journal (Recent Patents on Anti-Cancer Drug Discovery), published by Bentham Science Publishers.

namje@gist.ac.kr
Neuzil Jiri School of Medical Science Griffith University Queensland Australia j.neuzil@griffith.edu.au rpacdd_ebm_Pan-z-sa_001 Pan Zui College of Nursing and Health Innovation The University of Texas Arlington TX USA

Zui Pan received her PhD degree from Institute of Biophysics, the Chinese Academy of Sciences and postdoctoral training at Case Western Reserve University. She currently is Associate Professor with tenure in College of Nursing and Health Innovation, the University of Texas at Arlington. She is also Senior Member of National Academy of Inventors and members of 5 other professional organizations. Her research interest is focused on calcium signaling in cancer, heart and muscle diseases, which has been supported by NIH R01, S10, Texas STARs and other grants. Dr. Pan holds 2 patents and has 87 publications in peer-reviewed journals.

zui.pan@uta.edu
Papadimitriou Evangelia Department of Pharmacy University of Patras Patras Greece epapad@upatras.gr rpacdd_ebm_Pesce-sh_001 Pesce Antonio Orcid Unit of General Surgery Delta Hospital Lagosanto Italy 0000-0002-7560-551X 54920280600 https://scholar.google.com/citations?user=33xYkQ0AAAAJ&hl=it

Dr. Antonio Pesce is a general surgeon working at the Ospedale del Delta, Lagosanto, University of Ferrara, Italy. His Postgraduate Medical Specialty was in General Surgery at University of Catania, PhD in Basic and Applied Biomedical Sciences, curriculum in Experimental Surgery and Anatomy, University of Catania. In 2018, he obtained his national scientific qualification to Associate Professor. He trained in Italy, France and Sweden. He was awarded a Clinical and Research Fellowship at the Division of General, Digestive and Endocrine Surgery, Hôpital Saint Louis, Paris. He is affiliated to different research societies. He is involved in several research projects regarding fluorescence image guided surgery, experimental microsurgery, ERAS protocols in minimally-invasive surgery and colorectal cancer screening. He is author of several publications and book chapters.

nino.fish@hotmail.it
rpacdd_ebm_v-pittala_001 Pittalà Valeria Department of Drug and Health Sciences University of Catania Catania Italy

Dr. Pittalà attained her MSc in Chemical and Pharmaceutical Technologies, and subsequently completed her Ph.D. in Pharmaceutical Sciences at the University of Catania. Then, Dr. Pittalà moved to Milan (Italy) to join Pharmacia Corporation as a research scientist. She worked as member of Combinatorial Chemistry Group (R&D) and contributed to the discovery and identification of danusertib being co-inventor of bicyclopyrazoles chemical class. She currently hold the position of Assistant Professor at the University of Catania.

Here major area of interest are the design and synthesis of heme oxygenase-1 inhibitors, and σ receptor ligands as new antitumor agents. Her research resulted in 7 patents, over 60 peer-reviewed papers in prestigious journals. She is also serving as reviewer of several international journals.

vpittala@unict.it valeria.pittala@unict.it
Provenzano Maurizio Department of Urology University Hospital Zurich Zurich Switzerland maurizio.provenzano@usz.ch Pujol Maria D. Faculty of Pharmacy University of Barcelona Barcelona Spain mdpujol@ub.edu rpacdd_ebm_qin_001 Qin Jiang-Jiang College of Pharmaceutical Sciences Zhejiang Chinese Medical University Hangzhou China

Dr. Qin obtained his B.S. in Pharmaceutical Sciences and Ph.D. in Biomedical Engineering (Genetic Engineering Medicine and Natural Medicine) from School of Pharmacy, Shanghai Jiao Tong University. Currently, Dr. Qin is a Professor at College of Pharmaceutical Sciences, Zhejiang Chinese Medical University. He is also an Adjunct Professor at Institute of Cancer and Basic Medicine, Chinese Academy of Sciences. He has published more than 100 scientific papers and more than 20 meeting abstracts. Besides, Dr. Qin is an Associate Editor of Frontiers in Pharmacology and Frontiers in Oncology. He is also a reviewer of more than 40 peer-reviewed journals.

jqin@zcmu.edu.cn zylysjtu@hotmail.com
Raucher Drazen Department of Biochemistry University of Mississippi Medical Center MS USA draucher@umc.edu Robak Tadeusz Department of Hematology Medical University of Lodz Lodz Poland robaktad@csk.a.lodz.pl Russo Patrizia IRCCS “San Raffaele Pisana” Rome Italy patrizia_russo@hotmail.it rpacdd_ebm_saso-l_001 Saso Luciano Department of Physiology and Pharmacology Sapienza University Rome Italy

Prof. Luciano Saso is a Member of the Faculty of Pharmacy and Medicine, Sapienza University of Rome, Italy. He is author of more than 200 original scientific articles published in peer reviewed international journals with impact factor working mainly in the field of oxidative stress and antioxidants. He coordinated several international research projects and has been referee for many national and international funding agencies and international scientific journals in the last 25 years. He has been Guest Editor of several Special Issues.

luciano.saso@uniroma1.it
rpacdd_ebm_bendir_001 Segal-Bendirdjian Evelyne Université Paris Descartes Paris France

Received her MD from Necker Hospital (Paris Descartes University, France) and her PhD in Molecular and cellular Biology from Pierre and Marie Curie University (Paris, France). After working in Molecular and Biological Pharmacology in Gustave-Roussy Institute (Villejuif, France), she obtained a position as a research scientist at CNRS. She joined Saint-Louis Hospital (Paris, France) in 1998 where she became a team leader as a Research Director working on the pharmacological and physiological regulation of the telomerase expression and activity in an INSERM Unit. She joined Paris Descartes University in 2010 where she became the head of INSERM UMR-S 1007 named "Cellular Homeostasis and Cancer".

evelyne.segal-bendirdjian@inserm.fr
rpacdd_ebm_Shi-be_001 Shi Zhi Department of Cell Biology & Institute of Biomedicine Jinan University Jinan China

Dr. Shi obtained a doctorate (Ph.D.) and an MD degree from Sun Yat-Sen University, China. Currently, Dr. Shi is a Professor at Jinan University College of Life Science. He has published more than 80 scientific publications. Besides, he is an editorial board member of Molecular Pharmacology and a reviewer of more than 60 peer-reviewed journals.

tshizhi@jnu.edu.cn
rpacdd_ebm_sheikh-ms_001 Sheikh M. Saeed Department of Pharmacology Upstate Medical University Syracuse NY USA

Dr. M. Saeed Sheikh is a Professor in the Department of Pharmacology at State University of New York, Upstate Medical University, Syracuse, New York, USA. Research activities in Dr. Sheikh’s group are focused on the development of tumor markers and targets for cancer therapy. Work is also ongoing to elucidate the molecular mechanisms regulating cell death and survival signaling in normal and cancer cells to better understand the processes of cancer development and progression, and to develop novel, more efficacious and less toxic anticancer agents. Another related area is focused on genotoxic, ER and metabolic stresses.

sheikhm@upstate.edu
rpacdd_ebm_siddique-hr-aa_001 Siddique Hifzur R. Orcid Department of Zoology Aligarh Muslim University Aligarh India 0000-0001-8736-0487 56081338200 https://www.ncbi.nlm.nih.gov/pubmed/?term=Siddique+HR https://scholar.google.co.in/citations?user=AFA36U4AAAAJ&hl=en https://www.researchgate.net/profile/Hifzur_Siddique

Dr. HR Siddique completed his Master’s Degree from Aligarh Muslim University, Aligarh, India. He obtained his Ph.D. degree from the Indian Institute of Toxicology Research, Lucknow in the year 2008. He got his post-doctoral training in the University of Wisconsin, University of Minnesota & University of Southern California. His is specialized in the field of Stem Cells/Cancer Stem cells, therapy resistance Cancer & Chemosensitization, non-coding RNA, and Toxicology. He has numbers of Scientific articles published in highly reputed international journals. He has also delivered numbers of invited talks and 18-awards/honors to his credit.

hrsiddique@gmail.com hifzur.zo@amu.ac.in
rpacdd_ebm_Singh_001 Singh Deepika Department of Pharmaceutical Sciences Sam Higginbottom University of Agriculture, Technology and Sciences (SHUATS) Allahabad India

Deepika Singh, Ph.D is an Assistant Professor at the Department of Pharmaceutical Sciences, Faculty of Health Sciences, Sam Higginbottom University of Agriculture, Sciences and Technology, Allahabad, India. Her domain of research includes technology transfer, formulation of herbal drugs, nanostructured drug delivery system in the treatment of cancer. She has 11 years of teaching and research experience in the specialization of Pharmaceutics and Nanotechnology. She also authored various publications in reputed journals and book chapters. She has published almost 13 research papers and her publications have more than 116 citations.

deepi.chhoti@gmail.com
rpacdd_ebm_sun_001 Sun Xueying Department of General Surgery Harbin Medical University Harbin P.R. China

Dr Xueying Sun obtained MD and PhD from Shandong University in 1994. He is currently holding a professorial position at the Department of Surgery, the Affiliated Hospital of Harbin Medical University, and a position of Honorary Senior Research Fellow at Department of Molecular Medicine & Pathology, FMHS, University of Auckland. His present research and professional specialities include tumor hypoxia, cancer molecular targeted therapy, cellular signalling and non-coding RNAs. He was a winner of World Health Organization Fellowship (1999-2000) and Wellcome Trust Leave Fellowship (2001-2005). He has published over 200 research articles in peer-viewed journals including 120 articles in Science Citation Index journals. He is also a member of Editorial board of five academic journals, and a member of the review panels for National Natural Scientific Foundation, Ministry of Science and Technology and Ministry of Education of China.

kevsun88@hotmail.com k.sun@auckland.ac.nz
rpacdd_ebm_tiwari_001 Tiwari Amit K. Department of Pharmacology & Experimental Therapeutics University of Toledo Toledo OH USA

Dr. Tiwari did his Post-Doctoral training from Mount Sinai School of Medicine, NY. He is a tenured Associate Professor in the Department of Pharmacology and Experimental Therapeutics at the College of Pharmacy at UT, where he directs the Cancer and Systems Therapeutics program. Dr. Tiwari’s cancer pharmacology lab is focused on designing, characterizing (i.e. PK/PD) and developing targeted anticancer molecules against advanced multidrug-resistant cancers. In these areas, Dr. Tiwari holds 5 patent applications, has authored 110 peer-reviewed articles and presented over 150 presentations. Dr. Tiwari is an Editor and Editorial Board member of several journals. Dr. Tiwari’s research is supported by grants from federal agencies, International agencies, Private Foundations, and Pharmaceutical companies.

Amit.Tiwari@utoledo.edu
rpacdd_ebm_Tiwari_001 Tiwari Rakesh K. School of Pharmacy Chapman University,Harry and Diane Rinker Health Sciences Campus Irvine CA USA

Dr. Rakesh Kumar Tiwari is an Assistant Professor of Biopharmaceutical and Biomedical Sciences. He received his Ph.D. in Organic Chemistry from Dr. B.R. Ambedkar Center for Biomedical Research, University of Delhi, India, followed by his postdoctoral research at the College of Pharmacy, University of Rhode Island, Rhode Island. He has a keen interest in the interphase of chemistry and biology, focusing on using peptides and small molecules in solving biological problems. Dr. Tiwari has authored more than 100 peer-reviewed articles and has been a reviewer of dozens of high-impact peer-reviewed journals. Dr. Tiwari was awarded the 2013 research excellence postdoctoral award from the University of Rhode Island. He was also a recipient of the American Heart Association Postdoctoral Fellowship. He is a member of the American Chemical Society, American Association of Pharmaceutical Scientists, American Association for Advancement of Science, and American Peptide Society.

rakeshtiwarisir@gmail.com
Toninello Antonio Dipartimento di Scienze Biomediche University of Padova Padova Italy antonio.toninello@unipd.it antonio.toninello@unipd.it rpacdd_ebm_tonini_001 Tonini Giuseppe Department of Oncology University Campus Bio-Medico Rome Italy

Prof. Tonini, MD PhD, is Full Professor of Medical Oncology and Chief of the Division of Medical Oncology at Campus Bio-Medico University Hospital of Rome. He is Coordinator of the Degree Course in Medicine and Surgery, Director of the Post-Graduated School in Medical Oncology, Professor at Phd School of Integrated Biomedical Science and Bioethics and Director of the Translational Oncology Research Laboratory.

Current fields of investigation include clinical and molecular aspects of solid tumors, with particular attention to colorectal cancer, biliary tract cancer, bone metastases and palliative care in cancer.

Prof. Tonini is member of the Editorial Board or Editor in Chief of numerous high-ranked international journals and he has authored over 350 peer-reviewed manuscripts, reviews and book chapters on International Journals.

g.tonini@unicampus.it
Tulchinsky Eugene Department Cancer Studies and Molecular Medicine University of Leicester Leicester UK et32@leicester.ac.uk Vitale Giovanni Department of Clinical Sciences and Community Health University of Milan Milan Italy giovanni.vitale@unimi.it rpacdd_ebm_watanabe_001 Watanabe Masatoshi Division of Materials Science and Engineering Yokohama National University Tokiwadai Japan

Dr.Watanabe graduated from Yokohama National University, Faculty of Engineering, and Mie University, Faculty of Medicine. He obtained a doctor in Medicine from Mie University. He is also a guest professor, Yokohama City University. He has published more than 100 scientific publications.

mawata@ynu.ac.jp
Watanabe Takuya Tokyo University School of Medicine Tokyo Japan nabetaku@dia-net.ne.jp rpacdd_ebm_wolowiec-d_001 Wolowiec Dariusz Department of Hematology Medical University of Wroclaw Wroclaw Poland

Prof. Dariusz Wołowiec, MD, PhD, is graduated from the Faculty of Medicine, Wrocław Medical University, Poland. He holds a certification as a specialist in internal medicine, hematology and transplantation medicine. Currently he is appointed full-time professor in the Department of Hematology of Wrocław Medical University. In 1996-97 and 1992-95 he underwent a research training in Analytical Cytology Laboratory, Lyon I University, Lyon, France, where he obtained the doctorate (PhD) in Differentiation, Genetics and Immunology. He is an author or co-author of more than 100 publications in Polish and international peer-reviewed journals. His main field of interest is clinical and biological hematology, in particular lymphoid malignancies.

wolowiec@post.pl
Wong Kwong K. Department of Gynecologic Oncology and Reproductive Medicine The University of Texas M. D. Anderson Cancer Center Houston TX USA kkwong@mdanderson.org Ye Kaiming Department of Biomedical Engineering State University of New York Albany AR USA kye@binghamton.edu kye@binghamton.edu rpacdd_ebm_yu_001 Yu Yingyan Department of Surgery Shanghai Jiao Tong University Shanghai China

Prof. Yingyan Yu, M.D.; Ph.D. in tumor pathology (Okayama University, Japan, 1992), has over 200 international publications including 5 books. She was a research fellow at transplant pathology division of UPMC, Pittsburgh University, USA in 2002. Now, she works as a full professor in Ruijin hospital affiliated to Shanghai Jiao Tong University School of Medicine. Her research focuses on molecular pathology, AI-aided pathological diagnosis, tumor biomarker and biobank construction. Her group developed novel serum biomarker, urine biomarker and mouse models for cancer study. She is a board member of Chinese Anti-cancer Committee for Gastric Cancer; a board member of Chinese Anti-cancer Committee for Cancer Biospecimen Integration Research. She is editorial board member of Chinese Journal of Pathology; Chinese Journal of Gastrointestinal Surgery; World Journal of Gastrointestinal Oncology, etc. She was conferred multiple awards or honorary degrees by the Chinese Ministry of Education and Shanghai city government.

yingyan3y@sjtu.edu.cn
rpacdd_ebm_Yuan_001 Yuan Xi M. Department of Clinical and Experimental Medicine Linköping University Hospital Linkoping Sweden

Dr. Xi-Ming Yuan received his M.D. in 1984 from Jilin Medical College in China and a Ph.D. degree in internal medicine 1997 from Linkoping University, Sweden. Year 2006 he has been appointed Associate Professor in Experimental Pathology by Faculty of Medicine and Health Sciences, Linköping University. He has published more than 70 scientific publications in SCI that are cited > 1572 times with a h-index 23.

ximing.yuan@liu.se
rpacdd_ebm_Zhang-sh_001 Zhang Xiaoli Department of Biomedical Informatics The Ohio State University Columbus OH USA

Dr. Xiaoli Zhang is an Assistant Professor in the department of Biomedical Informatics at the Ohio State University (OSU) in the United States. She has a PhD in molecular Biology and a MS in statistics. Her research focuses on the discovery and development of novel diagnostic, prognostic, and therapeutic biomarkers and regimens for cancer treatment by using computational biology approach. Her expertise are in biological experiment designs, statistical and bioinformatics data analysis, as well as biological pathway analysis.

zhang.611@osu.edu Xiaoli.zhang@osumc.edu
rpacdd_ebm_zhang_001 Zhang Yunkai Department of Medicine Vanderbilt University Medical Center Nashville TN USA

Dr. Zhang obtained a doctorate (Ph.D.) in Pharmacology from St. John’s University, New York, USA. Dr. Zhang’s research is focused on understanding how drug resistance happens in cancer therapy and how to overcome it, using interdisciplinary (structural+genomic+biochemical) approaches. He is committed to revolutionize the basic biological research as a next generation biomedical data scientist. He has published more than 40 peer-reviewed publications. He is currently the editorial board member of this journal (Recent Patents on Anti-Cancer Drug Discovery), published by Bentham Science Publishers.

yunkai.zhang@vanderbilt.edu
rpacdd_ebm_Zhu-sh_001 Zhu Hua Department of Surgery The Ohio State University Wexner Medical Center Columbus OH USA

Dr. Zhu investigates the factors that control normal structure and intracellular signaling in cardiac and skeletal muscle physiology and diseases. He is interested in regulation of cell death pathways, such as necroptosis, apoptosis and autophagy for cardiac, skeletal muscle and corneal protection, and treating cancers; and how to rejuvenate stem cell (satellite cells and limbal stem cells) function to enhance tissue regeneration in the aging and injurious conditions.

Hua.Zhu@osumc.edu
Associate Editorial Board Members rpacdd_ebm_cao_001 Cao Hui-Ling Xi'an Medical University Xi'an China

Prof. Hui-Ling Cao obtained her Ph. D in structure biology direction at Northwestern Polytechnical University (Xi’an China) in 2013. In 2017, she obtained a professor position at the Institute of Basic and Translational Medicine, Xi’an Medical University. She also serves as a vice director in Institute of Basic and Translational Medicine and Shaanxi Key Laboratory of Ischemic Cardiovascular Disease. Her research interests include molecular pharmacology, anti-cancer or cardiovascular drug design concerning small molecular chemical drug and Chinese herb monomer drug and structure biology. Now she is the author of 30 research papers and presides over five research funds with more than three million RMB.

hlcao2009@126.com caohuiling_jzs@xiyi.edu.cn
rpacdd_ebm_Deshmukh-sh_001 Deshmukh Rahul R. LECOM-School of Pharmacy Bradenton FL USA

Prof. Rahul R. Deshmukh is an Assistant Professor of Pharmaceutical Sciences. He received his Master’s degree from University of Maryland, USA in 2009 and PhD degree from Wayne State University (WSU), USA in 2015. His research involves Drug Design and Discovery for Cancer, Combination Therapy for Cancer, Proteasome inhibitors for Solid Tumors, Immunotherapy for Cancer, Drug Repurposing, Natural Products and Phytochemicals. He has authored various papers, published in reputed journals.

rahulrdeshmukh@hotmail.com rdeshmukh@lecom.edu
acamc_ebm_ergun-s_001 Ergun Sercan Department of Medical Biology Ordu University Ordu Turkey

Sercan Ergun is working as Asst. Prof. Dr. in Department of Medical Biology, Bacis Sciences Division, Faculty of Medicine, Ordu University. He was included as researcher in a team studying briefly epigenetic changes in disease mechanisms of different types of cancers, including oncogenic/tumor suppressor gene and miRNA expression level changes, cell death mechanism analysis, development of some cancer therapy agents’ efficiencies via miRNAs. Also, He is analyzing some plant extracts and newly designed metal-bound compounds with respect to their anti-cancer potential and their effects on non-coding RNAs. Now, he is part (as a researcher) of a team studying on in silico miRNA and ceRNA analysis, miRNA heterogenetiy, piRNA expression changes in different cancer types , especially urological cancers.

sercanergun@msn.com sercanergun@odu.edu.tr
crr_abm_gaetano-p_001 Gaetano Piccolo Orcid Department of Surgery University of Catania Catania Italy 0000-0002-4942-7705 54585796900

Piccolo Gaetano was born on 23/05/1983 in Catania, Sicily, Italy. M.D, Postgraduate Medical Specialty in General Surgery, PhD at the Department of Surgery, University of Catania. Peer Review for: Medical Journal - OMICS Publishing Group, World Journal of Gastroenterology - Number ID 02953899, Annals of Hepatology, Frontiers of Medicine, BMJ Case Report, Surgical Oncology, World Journal of Surgery. Editorial Board Member for the International Journal of Gastroenterology Disorders & Therapy. Associate Editorial Board Member of Current Cancer Therapy Reviews. Author and Co-author of many publications. SCOPUS (H-Index 13). Scopus Author ID: 54585796900. ORCID ID https://orcid.org/0000-0002-4942-7705.

Schaky@hotmail.it gpiccolo1983@gmail.it
rpacdd_ebm_v-Kumar-sa_001 Kumar Vineet Lovely Professional University Jalandhar India

Vineet Kumar is currently working as Assistant Professor (Biotechnology) in the School of Bioengineering and Biosciences, LPU, Jalandhar, Punjab, India. His areas of interest include natural plant product based green synthesis of nanoparticles, nanotoxicity testing of nanoparticles and application of nanoparticles in drug delivery, food technology, sensing, dye degradation and catalysis. He has published many articles in these areas featuring in peer-reviewed reputed journals. He is also serving as editorial board member and reviewer for international peer reviewed journals. He has received various awards like senior research fellowship, best poster award and postdoctoral fellowship etc. He has published two books for CRC, Taylor & Francis Group and one book each for Elsevier and Springer.

vineetkumar22@gmail.com
crr_abm_vitale-sg_001 Vitale Salvatore G. Unit of Gynecology and Obstetrics, Department of General Surgery and Medical Surgical Specialties University of Catania Catania Italy

Dr. Salvatore Giovanni Vitale obtained his Ph.D. degree (in 2018) in Medical and Surgical Biotechnologies from the University of Messina, Italy. In 2018, he also obtained his national qualification to Associate Professor. Currently, Dr. Vitale is performing his services as a gynecologist at the “Policlinico Universitario” Hospital in Catania, Italy. His main research interests are as follows: intracavitary uterine pathology (including malignant pathology), reproductive biology, hysteroscopy, chronic pelvic pain, and gynecological endocrinology. Dr. Vitale, as an author/co-author, has published more than 160 articles in various journals, having over 1,715 total citations. Additionally, he has published numerous national / international monographs and book chapters that are used as reference texts in degree courses of medicine and health professions.

sgvitale@unict.it vitalesalvatore@hotmail.com
rpacdd_ebm_wang-s-sa_001 Wang Shanzhi Chemistry Department University of Arkansas Little Rock AR USA

Dr. Shanzhi Wang is a biochemist and enzymologist. He received his PhD of Biochemistry from Texas A&M University and did his postdoctoral research at Albert Einstein College of Medicine. His research focuses on enzyme kinetics and enzyme inhibitor design.

sxwang2@ualr.edu
rpacdd_ebm_jZhang-sh_001 Zhang Junhe Xinxiang Medical University Xinxiang China

Dr. Junhe Zhang is currently working as Assistant Professor (Biochemistry and Molecular Biology) in Xinxiang Medical University, Xinxiang, Henan Province, P.R. China. His areas of interest include gene expression regulation and gene therapy, especially for tumor gene therapy. He has published many articles in these areas in various journals. Additionally, he has also granted several China patents and participated in the compilation of two books. He is also serving as reviewers for international peer reviewed journals.

huaxingene@163.com zjh@xxmu.edu.cn, zhangjunhe@snnu.edu.cn
rpacdd_ebm_Zhao-Wei-sh_001 Zhao Wei Orcid Department of Biomedical Science City University of Hong Kong Kowloon Hong Kong 0000-0003-2421-7311

Dr. Zhao received his Ph. D. degree from Nanjing University in 2014.He has been an assistant professor at Nanjing Chest Hospital of Southeast University, Associate Professor at Chengdu Medical College and research assistant professor. He also stayed in Jingling Hospital as a postdoctoral fellows from 2016 to 2020. Dr. Zhao is a member of the editorial board of frontiers in oncology. His active research fields include (1) reversal of multidrug resistance induced by reprogrammed metabolism, (2) new drug research and development for treatment of cancer patients, (3) primary cancer tissue culture and test of drug sensitivity for personalized chemotherapy.

zw198626520@126.com wzhao42@cityu.edu.hk
Guest Editors crr_ebm_Chen-sh_001 Chen Zhe-Sheng St. John's University New York City NY USA

Dr. Chen obtained a doctorate (Ph.D.) in Pharmacology from the Kagoshima University, Japan. He also holds an MD degree from Guangdong Medical and Pharmaceutical College and a Master's degree in Toxicology from Sun Yat-Sen Medical University, China. Currently, Dr. Chen is a Professor at St. John’s University College of Pharmacy and Health Sciences. He is also a director of the Institute for Biotechnology at St. John’s University. He has published more than 180 scientific publications. Besides, he is the founding Editor in Chief of the Journal of Cancer Research Updates, an Editor-in-Chief of the Journal of New Developments in Chemistry and an editor of the African Journal of Pharmacy and Pharmacology. He is also an editorial board member of 26 journals and a reviewer of more than 170 peer-reviewed journals.

chenz@stjohns.edu
rpacdd_ebm_dou-qp_001 Dou Qingping P. Departments of Oncology, Pharmacology and Pathology School of Medicine Wayne State University Detroit MI USA

Dr. Q. Ping Dou is Professor of Oncology, Pharmacology and Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI. He obtained his Ph.D. degree in chemistry from Rutgers University, and postdoctoral training at Dana-Farber Cancer Institute and Harvard Medical School. Dr. Dou has extensive experience in the fields of molecular targeting, drug discovery, chemoprevention, natural products, proteasome inhibitors, cell cycle and apoptosis, and has published ~231 peer-reviewed research and review articles, many of those in journals of the highest quality. Dr. Dou is also an inventor of multiple US and international patents.

doup@karmanos.org
Executive Guest Editors rpacdd_ebm_khan-h-ah_001 Khan Haroon Orcid Department of Pharmacy Abdul Wali Khan University Mardan Pakistan

Dr. Khan is the full Professor at the Department of Pharmacy, Abdul Wali Khan University Mardan (AWKUM), Pakistan. In 17 years of professional experience, he has significantly contributed to the teaching and training of pharmacy graduate and pharmacy-related services. Dr. Khan remained the member of AWKUM syndicate, executive member of Pharmacy council of Pakistan(KP), and editorial member of more than 10 journals including Phytomedicine, Food and Chemical toxicology, and Metabolic Brain Disease. He is the author of more than 200 articles including editorial, review, research, and four books including one by Elsevier. Moreover, several post- graduate scholars are working under his supervision.

hkdr2006@gmail.com haroonkhan@awkum.edu.pk
© 2023 Bentham Science Publishers | Privacy Policy